Vimarsana
Biggest News Aggregation in the World

Page 2 - Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Consensus Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Consensus Statement Today - Breaking & Trending Today

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation - Vimarsana News

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC) held April 7-9 in Berlin, Germany. Four heart rhythm organizations from around the globe developed the statement.

What's new in concussion treatment and management - Vimarsana News

What's new in concussion treatment and management

There have been significant changes in the last few years in how concussions are identified and treated. Steven Broglio, director of the Michigan Concussion Center and professor at the U-M School of Kinesiology, can discuss.

Source: umich.edu
Latest advancements in identification and treatment of concussions - Vimarsana News

Latest advancements in identification and treatment of concussions

There have been significant changes in the last few years in how concussions are identified and treated. Steven Broglio, director of the Michigan Concussion Center and professor at the U-M School of Kinesiology, can discuss.

Medications Help Cut Risk Of Premature Death In ADHD Patients: Study - Vimarsana News

Medications Help Cut Risk Of Premature Death In ADHD Patients: Study

The latest study included 148,000 individuals in Sweden who were diagnosed with ADHD. The researchers noted that starting ADHD medications reduced their overall mortality risk, particularly from

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA - Vimarsana News

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company